Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Peter M. Lynch, MPH
Advertisement
Articles by Peter M. Lynch, MPH
A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
2
Bringing CAR T-Cell Therapy Into Community Cancer Centers
3
The True Cost of Running a Community CAR T-Cell Program
4
Trump Admin Awards $106M to Expand Rural Health Care in NY, RI, MI
5